Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders.
Allergan, Inc is a multi-specialty healthcare company.
A number of other large investors also recently modified their holdings of AGN. Fairbanks Capital Management Inc. increased its position in Allergan by 1.3% in the second quarter. Edgewood Management LLC now owns 4,445,924 shares of the company's stock valued at $911,192,000 after purchasing an additional 869,248 shares in the last quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company's stock valued at $5,551,128,000 after purchasing an additional 482,220 shares in the last quarter. Institutional owners hold 85.30% stake in the company, while insiders ownership held at 0.10%. Bank of The West now owns 25,316 shares of the company's stock worth $5,831,000 after buying an additional 4,896 shares during the period. Sumitomo Life Insurance Co. lifted its stake in shares of Allergan by 39.0% during the third quarter. The stock exchanged hands with 3,417,895 numbers of shares compared to its average daily volume of 3.72M shares. Fmr Ltd Liability Co holds 0.04% in National Oilwell Varco, Inc.
Chance of light snow in the area Friday . night
The initial band of rain showers with the front will move through eastern North Carolina early Wednesday morning. A slight risk of a wintry mix exists across far inland areas late Friday night and early Saturday.
Return-on-asset (ROA) for AGN is -6.00%, indicating its profitability situation relative to its assets.
Several equities research analysts have recently commented on AGN shares. 57,100 shares or 18.39% less from 69,971 shares in 2017Q1 were reported. The stock of Allergan plc (NYSE:AGN) has "Equal-Weight" rating given on Wednesday, September 20 by Morgan Stanley. UBS reaffirmed an "outperform" rating and issued a $275.00 price objective on shares of Allergan in a report on Wednesday, August 9th. Finally, Argus restated a "buy" rating and set a $280.00 target price on shares of Allergan in a research note on Monday, August 14th. A 5 analysts rate it as either a buy or a strong buy, while2 believe that investors should either steer clear of F or, if they already own its stock, sell it. Currently, the stock has a 1 Year Price Target of $229.9. Of all companies tracked, Allergan had the 0th highest net out-flow for the day. A higher P/E allows an investor to expect higher earnings growth compared to the companies with a lower P/E. Allergan plc, (reader can compare this with other companies that he is interested in). For the most recent quarter, quick ratio was 1.10, current ratio was 1.20, LT Debt/Equity ratio was 0.40 and Total Debt/Equity ratio stands at 0.46, while Payout ratio is 0.00.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the previous year, the business posted $3.04 EPS. Stockholders of record on Friday, November 17th will be paid a $0.70 dividend. The S&P 500 banks index.SPXBK surged 2.3 percent, while the Dow Jones Transport Average.DJT jumped 1.8 percent. The ex-dividend date of this dividend is Tuesday, May 16th. The 12 month volatility is now 23.736800. The SI to Allergan Plc's float is 2.38%. This repurchase authorization authorizes the company to repurchase up to 2.8% of its stock through open market purchases. On Tuesday, September 5 the stock rating was maintained by BMO Capital Markets with "Sell". The shares were sold at an average price of $220.45, for a total transaction of $416,430.05.
Trump calls on Saudis to lift Yemen blockade 'immediately'
Meanwhile, the Saudi-led coalition warplanes have since launched over 30 airstrikes on positions of Houthis inside and outside Sanaa, with no reports of casualties.
In other Allergan news, Director Christopher J. Coughlin bought 10,000 shares of Allergan stock in a transaction on Tuesday, December 5th. The average 1-year price target for (AGN) reveals an average price target of $231.86 per share. The disclosure for this sale can be found here.
ILLEGAL ACTIVITY WARNING: This news story was first published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another domain, it was stolen and republished in violation of US and worldwide copyright laws. Gemmer Asset Mgmt Limited Liability Corporation stated it has 0.01% in Allergan plc (NYSE:AGN).
No. 2 Kansas handed first defeat of season by Washington
Though it wasn't technically a home game for Kansas , the Jayhawks had won 35 of their last 44 games played at the Sprint Center. Junior guard Lagerald Vick scored a career-high 28 points, but Kansas (7-1) got little offensive help elsewhere.